Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Notes Payables (2016 - 2018)

Tg Therapeutics (TGTX) has 3 years of Notes Payables data on record, last reported at $67000.0 in Q4 2018.

  • For Q4 2018, Notes Payables fell 47.66% year-over-year to $67000.0; the TTM value through Dec 2018 reached $67000.0, down 47.66%, while the annual FY2018 figure was $67000.0, 47.66% down from the prior year.
  • Notes Payables reached $67000.0 in Q4 2018 per TGTX's latest filing, down from $91000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $224000.0 in Q1 2018 and bottomed at $67000.0 in Q4 2018.
  • Average Notes Payables over 3 years is $138238.6, with a median of $140284.0 recorded in 2017.
  • Peak YoY movement for Notes Payables: soared 85.84% in 2017, then plummeted 50.04% in 2018.
  • A 3-year view of Notes Payables shows it stood at $68875.0 in 2016, then skyrocketed by 85.84% to $128000.0 in 2017, then tumbled by 47.66% to $67000.0 in 2018.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $67000.0 in Q4 2018, $91000.0 in Q3 2018, and $210000.0 in Q2 2018.